ZappRx, Genentech partner to speed patient access to specialty drugs

ZappRx Inc. (Boston, Mass.) will use its digital platform in partnership with Genentech Inc. to improve patient access to specialty drugs for idiopathic pulmonary fibrosis (IPF) with a possible expansion to include allergic asthma and chronic idiopathic urticaria (CIU).

Genentech markets Esbriet pirfenidone for IPF and Xolair omalizumab for allergic asthma and CIU. ZappRx founder and CEO Zoë Barry told BioCentury the deal provides Genentech "deep insight into understanding how and why drugs are getting stuck in various stages of the [drug fulfillment] process." ...